Evidence map›Paper›PMID 35538327›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study.

Rebecca Pedersini, Manuel Zamparini, Sara Bosio, Pierluigi di Mauro, Antonella Turla, Sara Monteverdi, Alessandra Zanini, Vito Amoroso, Lucia Vassalli, Deborah Cosentini and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rebecca PedersiniMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy. rebecca.pedersini@gmail.com.ORCID http://orcid.org/0000-0001-5357-5703
Manuel ZampariniMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Sara BosioMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Pierluigi di MauroMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Antonella TurlaMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Sara MonteverdiMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Alessandra ZaniniMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Vito AmorosoMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Lucia VassalliMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Deborah CosentiniMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Salvatore GrisantiMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.
Edda Lucia SimonciniSSVD Breast Unit, ASST Spedali Civili of Brescia, Brescia, Italy.
Alfredo BerrutiMedical Oncology Department, ASST Spedali Civili of Brescia, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDysgeusia and taste alterations (TAs) are side effects of cytotoxic chemotherapy and affect patients' quality of life; however, the prevalence, types, and duration of TAs and their potential relationship with other clinical disturbances are not well-described. Our primary aim was to prospectively evaluate the characteristics of TAs in early breast cancer (EBC) patients during (neo)adjuvant chemotherapy and up to 1 year after its completion.

methodsFrom April 2014 to June 2018, 182 EBC patients entered the study and received (neo)adjuvant chemotherapy, mostly with taxane and anthracycline-containing regimens (65% of cases). A dietitian performed TAs assessment through the Common Terminology Criteria for Adverse Event v4.0 (CTCAE) and the Chemotherapy-induced Taste Alteration Scale (CiTAS) questionnaire during chemotherapy and follow-up according to defined time points: at baseline (T0, before starting chemotherapy); at the first follow-up visit, (T1, 2 months after starting chemotherapy); at the final follow-up visit (T2, 1 week after completing chemotherapy); after that, every 3 months up to 12 months.

resultsDysgeusia was reported by 69.8% of patients at T1 and declined subsequently; salty flavor distortion was the most frequently reported TA (51.6% of cases). CiTAS was significantly different between T0 and T2 (p < 0.001). Dysgeusia occurred more frequently in patients reporting nausea, mucositis, diarrhea, and appetite modification.

conclusionsTAs are common but transient during chemotherapy and occurred frequently with other distressing gastrointestinal side effects. The assessment of these side effects is crucial in managing EBC patients during (neo)adjuvant chemotherapy.

Indexed as

Antineoplastic AgentsBreast NeoplasmsChemotherapy, AdjuvantDysgeusiaFemaleFollow-Up StudiesHumansProspective StudiesQuality of LifeTasteAntineoplastic AgentsChemotherapy-induced toxicitiesDysgeusiaEarly breast cancerTaste alterations

Identifiers

PMID35538327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.